KIMIA BIOSCIENCES LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530313
₹32.00
Sept. 30, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #129 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
KIMIA BIOSCIENCES LIMITED (this stock) 151 20.1 42.5% -29.1% — 43 30 52

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹186 Cr
EV / EBITDA
12.4x
EV / Sales
1.66x
Market cap / Sales
1.35x
Earnings yield
4.97%

Quarterly Financials

↓ Negative
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 21 Cr, down 14.8% YoY.

↓ Negative
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 0 Cr, down 41.1% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 21 0 0 ₹0.0800
March 31, 2026 27 2 0 ₹0.1500
Dec. 31, 2025 30 5 — ₹1.1500
Sept. 30, 2025 34 1 — ₹0.2100
June 30, 2025 24 1 1 ₹0.1300
March 31, 2025 38 6 2 ₹0.4200
Dec. 31, 2024 30 4 5 ₹0.9700
Sept. 30, 2024 28 2 2 ₹0.3400
June 30, 2024 22 2 1 ₹0.3000
March 31, 2024 30 2 2 ₹0.3800
Dec. 31, 2023 26 -3 -2 ₹-0.4100
Sept. 30, 2023 24 -3 -2 ₹-0.5200
June 30, 2023 24 -4 -3 ₹-0.5700

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23
Total income (before exceptional items)21283034243931292231272524
Operating revenue21273034243830282230262424
Other income010-0100000110
Operating expenses18252431213025251926272626
Operating profit2373385344-1-2-2
Operating profit margin11.3%9.8%21.8%7.4%10.7%21.4%16.6%12.0%16.5%13.7%-4.0%-8.1%-6.8%
Depreciation1111111111111
Interest1110211111111
Exceptional items, gain / (loss)—————————————
Profit before tax0251164222-3-3-4
Tax01-0-004-1001-1-1-1
Net profit00——125212-2-2-3
EPS0.080.151.150.210.130.420.970.340.300.38-0.41-0.52-0.57
Net profit (TTM)————91093-1-5-13-12-9
EPS (TTM)1.591.641.911.731.862.031.990.61-0.25-1.12-2.80-2.57-1.82

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Total income (before exceptional items) — -2.9% 117†120†107†126†135†107†96†59†—
Operating revenue — -2.8% 115†119†105†125†133†106†94†59†—
Other income — — 2†1†2†1†2†1†2†0†—
Operating expenses — — 101†99†105†124†124†102†88†54†—
Operating profit — 11.2% 14†20†-0†1†8†4†5†5†—
Operating profit margin — — 12.4%†17.0%†-0.5%†0.5%†6.3%†4.2%†5.6%†7.9%†—
Depreciation — — 4†3†3†3†2†2†1†1†0†
Interest — — 4†5†5†4†3†3†2†0†—
Exceptional items, gain / (loss) — — 0†0†0†0†0†0†0†0†0†
Profit before tax — 8.9% 8†14†-7†-5†6†1†5†4†-1†
Tax — — 1†4†-2†-1†—————
Net profit — — —10†-5†-4†5†1†5†4†-1†
EPS — 8.7% 1.64†2.03†-1.12†-0.78†1.08†0.87†———

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24Mar 22Mar 21Mar 20Mar 19Mar 18Mar 17
Operating margin12.4%†17.0%†-0.5%†0.5%†6.3%†4.2%†5.6%†7.9%†—
EBIT margin10.4%†15.3%†-2.0%†-1.1%†6.7%†3.5%†7.1%†7.3%†—
PBT margin7.4%†11.5%†-6.8%†-4.0%†4.2%†1.2%†5.1%†6.9%†—
Net margin—8.1%†-5.1%†-3.0%†3.8%†1.3%†5.1%†6.9%†—
Interest coverage3.41x†3.99x†-0.42x†-0.38x†2.63x†1.48x†3.49x†19.88x†—
Dividend payout—————————
Earnings retention—————————
Current ratio1.04x0.92x———————
Quick ratio0.61x0.50x———————
Debt to equity1.95x3.27x———————
Return on equity—96.4%†———————
Return on assets—8.6%†———————
Return on capital employed28.5%†61.9%†———————
Asset turnover1.11x†1.07x†———————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 11 -8 -3 8 3
March 31, 2025 21 -5 -17 5 17

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 103 18 13 12 23 64 61 0 30 26
March 31, 2025 111 10 5 22 10 75 82 0 31 35

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.